Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cell ImpactOSTO:CI +19.03% Debt-to-EBITDA is -0.36 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 2,331 Industrial Products companies, Cell Impact ranks worse than 42900% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cell Impact's Debt-to-EBITDA or its related term are showing as below:
OSTO:CI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61 Med: -0.46 Max: -0.03
Current: -0.29
During the past 13 years, the highest Debt-to-EBITDA Ratio of Cell Impact was -0.03. The lowest was -0.61. And the median was -0.46.
OSTO:CI's Debt-to-EBITDA is ranked worse than 100% of 2331
companies
in the Industrial Products industry
Industry Median: 1.69
vs OSTO:CI: -0.29
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cell Impact Debt-to-EBITDA Related Terms
Cell Impact Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cell Impact's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CI vs CRS, ATI, MLI: Debt-to-EBITDA Comparison
For the Metal Fabrication subindustry, Cell Impact's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Impact Debt-to-EBITDA vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Cell Impact's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cell Impact's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Cell Impact (OSTO:CI) has a Debt-to-EBITDA of -0.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cell Impact. According to the industry distribution chart, Cell Impact ranks #999999 out of 2331 companies in the Industrial Products industry.
Is Cell Impact's Debt-to-EBITDA too high?
Cell Impact's current Debt-to-EBITDA is -0.36. Based on the distribution chart, Cell Impact ranks #999999 out of 2331 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Cell Impact's Debt-to-EBITDA compare to CRS and ATI?
According to the Industrial Products industry distribution chart, Cell Impact ranks #999999 out of 2331 companies for Debt-to-EBITDA. This places Cell Impact in the lower half of its industry. The industry median Debt-to-EBITDA is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Industrial Products company?
The median Debt-to-EBITDA among Industrial Products companies is 1.69, based on 2,331 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cell Impact. For the Industrial Products industry, the median Debt-to-EBITDA is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Impact's current Debt-to-EBITDA is -0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Impact stock overvalued right now?
Based on GuruFocus' analysis, Cell Impact (OSTO:CI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.07 — trading 42.6% above its estimated fair value. The current Debt-to-EBITDA is -0.36. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cell Impact (OSTO:CI), the current Debt-to-EBITDA is -0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cell Impact develops and manufactures flow plates for fuel cells and electrolyzers using materials such as graphite, stainless steel, and titanium. The company has developed and patented a high-velocity forming method, known as Cell Impact Forming, which enables the production of flow plates with advanced designs. Geographically, it operates in Sweden, Asia, the U.S., and Other Europe. It generates the majority of its revenue from Sweden.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CI has been successfully added to your 
